Details of the Drug

General Information of Drug (ID: DMRKE63)

Drug Name

Chlorambucil

Synonyms

Ambochlorin; Amboclorin; Chlocambucil; Chloorambucol; Chlorambucilum; Chloraminophen; Chloraminophene; Chlorbutin; Chlorbutine; Chlorbutinum; Chloroambucil; Chlorobutin; Chlorobutine; Clorambucile; Clorambucilo; Ecloril; Elcoril; Elcorin; Leukeran; Leukersan; Leukoran; Linfolizin; Linfolysin; Lympholysin; Clorambucile [DCIT]; Glaxo Wellcome Brand of Chlorambucil; GlaxoSmithKline Brand of Chlorambucil; Leuk ersan; Leukeran tablets; Phenylbutyric acid nitrogen mustard; Wellcome Brand of Chlorambucil; C0253; CB 1348; CB1348; Cb l348; CB-1348; Chlorambucil [INN:BAN]; Chlorambucilum [INN-Latin]; Clorambucilo [INN-Spanish]; LEUKERAN (TN); Leukeran (TN); Phenylbuttersaeure-lost; Phenylbuttersaeure-lost[German]; Chlorambucil (USP/INN)

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Approved	[1], [2]

Therapeutic Class

Anticancer Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

304.2

Topological Polar Surface Area (xlogp)

1.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 82% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 2.8 mL/min/kg [5]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.65742 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.01% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.26 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 12 mg/mL [3]

Chemical Identifiers

Formula: C14H19Cl2NO2
IUPAC Name: 4-[4-[bis(2-chloroethyl)amino]phenyl]butanoic acid
Canonical SMILES: C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
InChI: InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)
InChIKey: JCKYGMPEJWAADB-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2708
ChEBI ID: CHEBI:28830
CAS Number: 305-03-3
DrugBank ID: DB00291
TTD ID: D0V8QT
VARIDT ID: DR00895
INTEDE ID: DR0297
ACDINA ID: D00119

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA replication (DNA repli)	TTABD5E	NOUNIPROTAC	Intercalator	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[8]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Glutathione S-transferase pi (GSTP1)_{Main DME}	DEK6079	GSTP1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Chlorambucil (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Chlorambucil and Roflumilast.	Asthma [CA23]	[35]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[36]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[36]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[36]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[36]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[36]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[36]
ABT-492	DMJFD2I	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[36]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[36]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[36]
Grepafloxacin	DMGLX0T	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Grepafloxacin.	Bronchitis [CA20]	[36]
Amphotericin B	DMTAJQE	Moderate	Increased risk of nephrotoxicity by the combination of Chlorambucil and Amphotericin B.	Fungal infection [1F29-1F2F]	[37]
Teriflunomide	DMQ2FKJ	Major	Additive myelosuppressive effects by the combination of Chlorambucil and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[38]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Chlorambucil and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[37]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Chlorambucil and Denosumab.	Low bone mass disorder [FB83]	[39]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Chlorambucil and Thalidomide.	Multiple myeloma [2A83]	[40]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Chlorambucil and Tecfidera.	Multiple sclerosis [8A40]	[41]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Chlorambucil and Siponimod.	Multiple sclerosis [8A40]	[37]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Chlorambucil and Fingolimod.	Multiple sclerosis [8A40]	[42]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Chlorambucil and Ocrelizumab.	Multiple sclerosis [8A40]	[43]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Chlorambucil and Ozanimod.	Multiple sclerosis [8A40]	[35]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Chlorambucil and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[44]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[36]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Chlorambucil and Canakinumab.	Rheumatoid arthritis [FA20]	[45]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Chlorambucil and Rilonacept.	Rheumatoid arthritis [FA20]	[45]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Chlorambucil and Golimumab.	Rheumatoid arthritis [FA20]	[46]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Chlorambucil and Leflunomide.	Rheumatoid arthritis [FA20]	[38]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Chlorambucil when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[47]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Chlorambucil and Azathioprine.	Transplant rejection [NE84]	[37]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[36]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Chlorambucil and Plazomicin.	Urinary tract infection [GC08]	[37]
Enoxacin	DMYTE6L	Minor	Decreased absorption of Chlorambucil due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[36]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Chlorambucil and Ganciclovir.	Virus infection [1A24-1D9Z]	[37]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Chlorambucil and Valganciclovir.	Virus infection [1A24-1D9Z]	[37]
-----------


⏷ Show the Full List of 34 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Chlorambucil 2 mg tablet	2 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7143).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010669.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther. 2009 Jun;8(6):1714-23.
8	Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol. 2004;44:137-66.
9	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
10	The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants. J Mol Biol. 2008 Jun 27;380(1):131-44.
11	Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
12	Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
13	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
14	Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9.
15	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
16	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
17	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
18	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
19	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
20	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
21	Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
22	Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
23	Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
24	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
25	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
26	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
27	Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
28	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
29	Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
30	Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
31	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
32	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
33	Stationary potential of the brain: Part II. Clinical studies. Neurol Med Chir (Tokyo). 1979 Jul;19(7):655-64.
34	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
35	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
36	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
37	Cerner Multum, Inc. "Australian Product Information.".
38	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
39	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
40	Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
41	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
42	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
43	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
44	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
45	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
46	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
47	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]